EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.

J&J failed to convince BBB National Program’s appeals panel a 2008 NAD decision supporting its “#1 dermatologist recommended” claim for Neutrogena should preclude another review. Panel says market has changed in 12 years since review of Unilever challenge and L’Oreal could make its own challenge.

Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.